XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
This new facility strengthens Latin America as a collaborative hub
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
Subscribe To Our Newsletter & Stay Updated
